Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival

The disruption of the circadian timing system (CTS), which rhythmically controls cellular metabolism and proliferation, accelerated experimental cancer progression. A measure of CTS function in cancer patients could thus provide novel prediction information for outcomes, and help to identify novel specific therapies. The rest-activity circadian rhythm is a reliable and non-invasive CTS biomarker, which was monitored using a wrist watch accelerometer for 2 days in 436 patients with metastatic colorectal cancer. The relative percentage of activity in-bed versus out-of-bed (I < O) constituted the tested CTS measure, whose prognostic value for overall survival (OS) and progression-free survival (PFS) was determined in a pooled analysis of three patient cohorts with different treatment exposures. Median OS was 21.6 months [17.8–25.5] for patients with I < O above the median value of 97.5% as compared to 11.9 months [10.4–13.3] for those with a lower I < O (Log-rank p < 0.001). Multivariate analyses retained continuous I < O as a joint predictor of both OS and PFS, with respective hazard ratios (HR) of 0.954 (p < 0.001) and 0.970 (p < 0.001) for each 1% increase in I < O. HRs had similar values in all the patient subgroups tested. The circadian physiology biomarker I < O constitutes a robust and independent quantitative predictor of cancer patient outcomes, that can be easily and cost-effectively measured during daily living. Interventional studies involving 24-h schedules of clock-targeted drugs, light intensity, exercise and/or meals are needed for testing the relevance of circadian synchronization for the survival of patients with disrupted rhythms.

[1]  P. Achermann,et al.  Concepts and models of sleep regulation: an overview , 1992, Journal of sleep research.

[2]  S. Iacobelli,et al.  Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. , 2009, Cancer research.

[3]  G. Atkinson,et al.  The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients. , 1996, Chronobiology international.

[4]  Jordi Rovira Simón,et al.  The European InCASA telecare-telehealth electronic platform (ICT-FP7) for the daily assessment of symptoms, weight, and activity in cancer patients on chronotherapy at home. , 2012 .

[5]  J Lellouch,et al.  Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  H. Kraemer,et al.  Effects of supportive-expressive group therapy on pain in women with metastatic breast cancer. , 2009, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[7]  Kathryn A. Lee,et al.  Methodological challenges when using actigraphy in research. , 2008, Journal of pain and symptom management.

[8]  Jean Clairambault,et al.  Circadian timing in cancer treatments. , 2010, Annual review of pharmacology and toxicology.

[9]  F. Lévi,et al.  Effects of meal timing on tumor progression in mice. , 2004, Life sciences.

[10]  F. Lévi,et al.  Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Peng Huang,et al.  The Circadian Gene Period2 Plays an Important Role in Tumor Suppression and DNA Damage Response In Vivo , 2002, Cell.

[12]  D. Spiegel Mind matters in cancer survival. , 2011, JAMA.

[13]  Albert Goldbeter,et al.  Implications of circadian clocks for the rhythmic delivery of cancer therapeutics , 2008, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[14]  J. Wagner Strategic approach to fit-for-purpose biomarkers in drug development. , 2008, Annual review of pharmacology and toxicology.

[15]  C. Pollak,et al.  The role of actigraphy in the study of sleep and circadian rhythms. , 2003, Sleep.

[16]  F. Lévi,et al.  Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer , 1997, The Lancet.

[17]  F. Lévi,et al.  Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. , 2006, The oncologist.

[18]  C. Jaffe Measures of response: RECIST, WHO, and new alternatives. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Spiegel Losing sleep over cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Stefano Iacobelli,et al.  Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Francis Lévi,et al.  Host circadian clock as a control point in tumor progression. , 2002, Journal of the National Cancer Institute.

[23]  C. Koopman,et al.  A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer , 2007, Biological Psychology.

[24]  S. Iacobelli,et al.  Prediction of overall survival through circadian rest‐activity monitoring during chemotherapy for metastatic colorectal cancer , 2012, International journal of cancer.

[25]  F. Cognetti,et al.  Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. , 2006, European journal of cancer.

[26]  Pasquale F Innominato,et al.  Circadian Disruption, Fatigue, and Anorexia Clustering in Advanced Cancer Patients: Implications for Innovative Therapeutic Approaches , 2009, Integrative cancer therapies.

[27]  Sandrine Dulong,et al.  Tumor and Stem Cell Biology Cancer Inhibition through Circadian Reprogramming of Tumor Transcriptome with Meal Timing , 2022 .

[28]  D. Sargent,et al.  Biomarkers and surrogate end points—the challenge of statistical validation , 2010, Nature Reviews Clinical Oncology.

[29]  K. Straif,et al.  Painting, firefighting, and shiftwork. , 2010, IARC monographs on the evaluation of carcinogenic risks to humans.

[30]  U. Schibler,et al.  The mammalian circadian timing system: organization and coordination of central and peripheral clocks. , 2010, Annual review of physiology.